6-Bromo-3-hydroxypyrazine-2-carboxamide

6-Bromo-3-hydroxypyrazine-2-carboxamide (CAS 259793-88-9) is a favipiravir intermediate supplied by Hunan HuaTeng Pharmaceutical Co., Ltd. at pharmaceutical grade under in-house standards; favipiravir is an antiviral compound developed by Toyama Chemical (Fujifilm group) that was studied in China as an experimental COVID-19 treatment in 2020. The supplier is not the manufacturer, and the compound is distributed to North America, Central/South America, Western Europe, Eastern Europe, and Asia.